US Predictors of Papillary Thyroid Microcarcinoma Progression at Active Surveillance

医学 危险系数 甲状腺 内科学 肿瘤进展 前瞻性队列研究 比例危险模型 血管性 甲状腺癌 肿瘤科 癌症 外科 置信区间
作者
Ji Ye Lee,Ji‐hoon Kim,Yeo Koon Kim,Chang Yoon Lee,Eun Kyung Lee,Jae Hoon Moon,Hoon Choi,Yul Hwangbo,Sun Wook Cho,Su‐jin Kim,Kyu Eun Lee,Do Joon Park,Young Joo Park
出处
期刊:Radiology [Radiological Society of North America]
卷期号:309 (1) 被引量:8
标识
DOI:10.1148/radiol.230006
摘要

Background Active surveillance (AS) is an accepted strategy for patients with low-risk papillary thyroid microcarcinoma (PTMC). While previous studies have evaluated the prognostic value of US features, results have been inconsistent. Purpose To determine if US features can help predict tumor progression in patients with low-risk PTMC undergoing AS. Materials and Methods This prospective study enrolled 1177 participants with PTMC from three hospitals between June 2016 and January 2021. Participants were self-assigned to either immediate surgery or AS, and those with two or more US examinations in the absence of surgery were included in the analysis. A χ2 test was used to compare estimated tumor progression rate at 4 years between participants stratified according to US features. Multivariable Cox regression analysis was used to assess the association of clinical and US features with overall tumor progression and specific progression criteria. Results Among 699 participants included in the analysis, 68 (mean age, 49 years ± 12 [SD]; 40 female participants) showed tumor progression (median follow-up, 41.4 months ± 16 [SD]). Tumor progression was associated with the US features of diffuse thyroid disease (DTD) (hazard ratio [HR], 2.3 [95% CI: 1.4, 3.7]; P = .001) and intratumoral vascularity (HR, 1.7 [95% CI: 1.0, 3.0]; P = .04) and the participant characteristics of male sex (HR, 2.8 [95% CI: 1.7, 4.6]; P < .001), age less than 30 years (HR, 2.9 [95% CI: 1.2, 6.8]; P = .01), and thyroid-stimulating hormone level of 7 µU/mL or higher (HR, 6.9 [95% CI: 2.7, 17.4]; P < .001). The risk of tumor progression was higher for participants with DTD (14%, P = .001) or intratumoral vascularity (14%, P = .02) than for participants without these features (6%). DTD and intratumoral vascularity were associated with tumor enlargement (HR, 2.7 [95% CI: 1.4, 5.1]; P = .002) and new lymph node metastasis (HR, 5.0 [95% CI: 1.3, 19.4]; P = .02), respectively. Conclusion DTD and intratumoral vascularity were associated with an increased risk of tumor progression in participants with PTMC undergoing AS. Clinical trial registration no. NCT02938702 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Reuter and the review "International Expert Consensus on US Lexicon for Thyroid Nodules" by Durante et al in this issue.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
啵噜噜噜啊完成签到,获得积分10
4秒前
OYY完成签到 ,获得积分10
4秒前
烂漫的断秋完成签到 ,获得积分10
5秒前
6秒前
6秒前
Lucas应助Livrik采纳,获得10
7秒前
cyn0762完成签到,获得积分10
7秒前
点到为止完成签到,获得积分10
8秒前
9秒前
Akim应助lll采纳,获得10
10秒前
高贵灵槐完成签到 ,获得积分10
11秒前
14秒前
wxh完成签到 ,获得积分20
14秒前
量子星尘发布了新的文献求助10
14秒前
liuzi发布了新的文献求助20
15秒前
雨过天晴完成签到,获得积分10
16秒前
花花完成签到 ,获得积分10
17秒前
18秒前
20秒前
汪汪发布了新的文献求助10
23秒前
23秒前
24秒前
27秒前
追寻筮关注了科研通微信公众号
27秒前
miaojuly发布了新的文献求助10
28秒前
充电宝应助汪汪采纳,获得10
29秒前
30秒前
涵哈哈哈哈哈完成签到 ,获得积分10
32秒前
34秒前
liuzi完成签到,获得积分10
34秒前
科目三应助油菜的星星采纳,获得10
36秒前
36秒前
36秒前
37秒前
37秒前
木心应助高院士采纳,获得60
38秒前
38秒前
38秒前
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035